Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,527 across all filing types
Latest filing 2014-06-12 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2013年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2013 annual equity distribution plan (dividend distribution) of 华兰生物工程股份有限公司. It details the dividend amount per share, the record date, the ex-dividend date, the eligible shareholders, and the method of dividend payment. The document is relatively short (1457 characters) and focuses on the dividend distribution details rather than presenting full financial statements or comprehensive annual report content. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2014-06-12 Chinese
关于获批设置单采血浆站的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval to set up a single plasma collection station. It includes details about the approval from a provincial health department and plans for construction and registration. The document is short (549 characters) and does not contain financial data, financial results, or detailed reports. It is an operational update related to company activities but does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial or governance disclosures. It is not a report publication announcement since it does not mention any report being published or attached. The content is an official announcement about a business operation approval, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2014-05-09 Chinese
2013年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and proceedings of the 2013 Annual General Meeting (AGM) of 华兰生物工程股份有限公司. It details the legality of the meeting's convening, attendance, proposals, voting procedures, and results. The document does not contain financial statements or detailed financial performance data but focuses on the validation and legality of the AGM process and voting outcomes. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at general meetings. The document length is 2628 characters, which is relatively short and consistent with a voting results announcement rather than a full report or presentation. Therefore, the correct classification is DVA.
2014-04-28 Chinese
2013年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a 2013 Annual General Meeting (AGM) resolution announcement for 华兰生物工程股份有限公司. It details the date, location, voting methods, attendance, and the voting results on various proposals including the 2013 annual reports, financial statements, profit distribution, appointment of auditors, and changes in independent directors. The document is a formal announcement of the voting results and resolutions passed at the AGM, not the full AGM materials or reports themselves. The document length is 3249 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2014-04-28 Chinese
2014年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2014 First Quarter Report" of the company 华兰生物工程股份有限公司. It contains detailed financial data for the quarter, including revenue, net profit, earnings per share, cash flow, and changes in shareholders. It also includes explanations of significant changes in financial statement items, shareholder information, and management's outlook for the next half year. The length of the document is substantial (15,000 characters), and it contains actual financial statements and substantive financial data and analysis for a period shorter than a full fiscal year (the first quarter of 2014). This matches the definition of an Interim / Quarterly Report (IR). It is not a mere announcement or certification, but a full quarterly report with detailed financials and management commentary. Q1 2014
2014-04-25 Chinese
2014年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2014 年第一季度报告全文" which translates to "2014 First Quarter Report Full Text." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and detailed financial data for the first quarter of 2014. The presence of actual financial data, comprehensive financial metrics, and quarterly period references clearly indicate this is a quarterly financial report. The length of the document (15,000 characters) and the detailed financial disclosures confirm it is not merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2014
2014-04-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.